What is trastuzumab deruxtecan's activity for patients with CNS+ disease?

Is there evidence that T-DXd crosses the blood-brain barrier?

Community PollStarted

In a patient with metastatic HER2-low breast cancer, would the presence of brain metastases change your decision to use T-DXd?

92 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers

Mednet Member

Medical Oncology · Cleveland Clinic

Answered on

The DESTINY-Breast04 trial excluded patients with active CNS metastases so the study does not provide information on the activity of this drug in HER2-low CNS disease. In HER2-positive disease, however, CNS activity has been observed with trastuzumab deruxtecan; among patients evaluated for CNS resp...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · Washington University School of Medicine

Answered on

In HER2 amplified patients with stable brain metastasis, T-DXd was associated with similar PFS compared to those without brain metastasis in the DESTINY-Breast03, therefore suggesting activity of T-DXd in brain mets.

Join for free or sign in to see the full answer

Mednet Member

Medical Oncology · University of Iowa Holden Comprehensive Cancer Center

Answered on · Updated on

Drug-antibody conjugates do have the ability to cross blood brain barrier and Trastuzumab-deruxtecan (T-DXd) has shown impressive intracranial activity across multiple studies.

A subgroup analysis of 24 patients with brain metastases in DESTINY-Breast 01, reported intracranial objective response of ...

Join for free or sign in to see the full answer